medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2013, Number 607

<< Back Next >>

Rev Med Cos Cen 2013; 70 (607)

Miocardiopatía hipertrófica

Callau BWM

Language: Spanish
References: 17
Page: 429-435
PDF size: 180.94 Kb.


ABSTRACT

Hypertrophic cardiomyopathy is a genetic disease caused by mutations in genes encoding sarcomeric proteins. It is characterized by left ventricular hypertrophy, typically of a nondilated chamber, without obvious cause. The clinical course is variable with the potential for clinical presentation during all phases of life, from infancy to old age. Many affected people are asymptomatic; on the other hand, patients may develop symptoms of heart failure and functional limitation, the most frequent complaint is dyspnea. Hypertrophic cardiomyopathy is the most common cause of sudden death in young population, including competitive athletes and unfortunately it could be the first clinical manifestation. Diagnosis is made with cardiac imaging. All patients should undergo comprehensive risk stratification at initial evaluation.


REFERENCES

  1. Braundwald E. Tratado de cardiología: Vol 2. 8 ª Ed. Barcelona: Elsevier; 2009

  2. Brenes C. El electrocardiograma normal y patológico. San José: Editorial UCR; 2009

  3. Brugada J. Muerte súbita en la miocardiopatía hipertrófica. Rev Esp Cardiol 1998; 51: 991-996

  4. Fifer M, Vlahakes G. Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008; 117: 429-439

  5. Fuster V, O’Rourke R, Alexander R, Roberts R, King S, Prystowsky E. Manual de cardiología: Hurst el corazón. 11 ª Ed. Madrid: McGraw-Hill; 2005

  6. Gersh B, Marron B, Bonow R, Dearani J, Fifer M, Link M, et al. 2011 ACCF/ AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Circulation 2011; 124: 00-00

  7. Johnson J, Grifoni C, Bos J, Saber- Ayad M, Ommen S, Nistri S, et al. Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J 2011; 32, 1114-1120

  8. Lilly L. Fisiopatología de las cardiopatías. 4ª Ed. Barcelona: Lippincott Williams & Wilkins; 2007

  9. Loscalzo J. Harrison’s Cardiovascular Medicine. New York: McGraw-Hill; 2010

  10. Maron B. Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy. Circulation 2010; 121: 445-456

  11. Maron B, Mathenge R, Casey S, Poliac L, Longe T. Clinical profile of hypertrophic cardiomyopathy indentified de novo in rural communities. JACC 1999; 33: 1590-1595

  12. McKenna W, Monserrat L. Identificación y tratamiento de los pacientes con miocardiopatía hipertrófica y riesgo de muerte súbita. Rev Esp Cardiol 2000; 53: 123-130

  13. Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J 2010; 31, 2111-2123

  14. Montijano A, Bouzas B, Penas M, McKenna W. Estrategias terapéuticas en la miocardiopatía hipertrófica obstructiva sintomática. Rev Esp Cardiol 2001; 54: 1311-1326

  15. Navarro-Lopez F. Miocardiopatía hipertrófica: Bases genéticas e implicaciones clínicas. Rev Esp Cardiol 2004; 57(supl 1): 22-32

  16. Noureldin R, Liu S, Nacif M, Judge D, Halushka M, Abraham T, et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012; 14: 17

  17. Topol E. Tratado de medicina cardiovascular. 3ª Ed. Barcelona: Lippincott Williams & Wilkins; 2008




2020     |     www.medigraphic.com